Zosyn Dosing for Hospital-Acquired Pneumonia
For moderate-to-severe hospital-acquired pneumonia in adults, administer piperacillin-tazobactam (Zosyn) 4.5 grams IV every 6 hours, infused over 30 minutes, for a duration of 7-14 days. 1, 2
Standard Dosing Regimen
Base regimen: Piperacillin-tazobactam 4.5 grams IV every 6 hours (totaling 18 grams piperacillin/2 grams tazobactam daily), administered as a 30-minute infusion 1, 3, 2
Treatment duration: 7-14 days for nosocomial pneumonia 2
- For patients responding adequately, treatment should not exceed 8 days 4
- Clinical stability criteria include temperature ≤37.8°C, heart rate ≤100 bpm, respiratory rate ≤24 breaths/min, and systolic BP ≥90 mmHg 5
Risk-Based Coverage Additions
MRSA Coverage (Add if ANY of these present):
- Prior IV antibiotic use within 90 days 1, 6
- MRSA prevalence >20% in your unit (or unknown prevalence) 1, 6
- Prior MRSA colonization/infection 1, 6
- Septic shock at presentation 1, 6
- ARDS preceding pneumonia 1
Add: Vancomycin 15 mg/kg IV every 8-12 hours (target trough 15-20 mg/mL) OR linezolid 600 mg IV every 12 hours 1, 3, 6
Double Antipseudomonal Coverage (Add if ANY of these present):
- Prior IV antibiotic use within 90 days 1, 6
- Septic shock at presentation 1, 6
- ARDS preceding pneumonia 1
- ≥5 days hospitalization before pneumonia onset 1
- Acute renal replacement therapy 1
- Structural lung disease (bronchiectasis, cystic fibrosis) 1
Add ONE of:
- Ciprofloxacin 400 mg IV every 8 hours 1, 3
- Levofloxacin 750 mg IV daily 3
- Amikacin 15-20 mg/kg IV every 24 hours 1, 3
- Gentamicin 5-7 mg/kg IV every 24 hours 1, 3
Renal Dose Adjustments
The FDA label mandates dose reduction for creatinine clearance ≤40 mL/min: 2
| CrCl (mL/min) | Nosocomial Pneumonia Dose |
|---|---|
| >40 | 4.5 g IV every 6 hours |
| 20-40 | 3.375 g IV every 6 hours |
| <20 | 2.25 g IV every 6 hours |
| Hemodialysis | 2.25 g IV every 8 hours + 0.75 g after each dialysis session |
| CAPD | 2.25 g IV every 8 hours |
Pharmacokinetic Optimization
Extended infusions (4-hour infusions instead of 30-minute infusions) may improve outcomes in critically ill patients with severe infections, particularly when treating Pseudomonas aeruginosa with MIC 8-16 mcg/mL. 7, 8
- Extended-infusion dosing: 3.375 g IV infused over 4 hours every 8 hours 7
- This approach reduced 14-day mortality from 31.6% to 12.2% in critically ill patients with APACHE-II scores ≥17 7
- Alveolar penetration is 40-50% of serum concentrations 9
Critical Pitfalls to Avoid
Do NOT use piperacillin-tazobactam monotherapy for Pseudomonas aeruginosa pneumonia—combination with an aminoglycoside is mandatory per FDA labeling. 2
Do NOT add routine anaerobic coverage (e.g., metronidazole)—piperacillin-tazobactam already provides adequate anaerobic coverage for hospital-acquired pneumonia. 5
Do NOT continue aminoglycoside beyond 5-7 days if patient is improving and Pseudomonas is not isolated. 4
Do NOT delay antibiotics waiting for cultures—this is a major risk factor for excess mortality. 5
Monitoring and De-escalation
- Obtain respiratory cultures before initiating antibiotics 1
- Reassess at 48-72 hours based on culture results and clinical response 5
- Switch to oral therapy when hemodynamically stable, improving clinically, able to take oral medications, and have functioning GI tract 5
- Narrow therapy based on culture results to avoid unnecessary broad-spectrum coverage 1, 4